{"id":70253,"date":"2026-07-20T11:17:22","date_gmt":"2026-07-20T03:17:22","guid":{"rendered":"https:\/\/flcube.com\/?p=70253"},"modified":"2026-07-20T11:17:24","modified_gmt":"2026-07-20T03:17:24","slug":"jacobio-launches-phase-ib-iii-trial-of-pan-kras-inhibitor-jab-23e73-for-kras-mutated-pancreatic-cancer-in-partnership-with-astrazeneca","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70253","title":{"rendered":"Jacobio Launches Phase Ib\/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jacobio Pharmaceuticals Group Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1167:HKG\">HKG: 1167<\/a>) announced that the first patient has been dosed in a <strong>Phase Ib\/III clinical trial<\/strong> in China evaluating <strong>JAB-23E73<\/strong>, an <strong>orally administered pan-KRAS inhibitor<\/strong>, in combination with <strong>nab-paclitaxel and gemcitabine<\/strong> for the <strong>first-line treatment of KRAS-mutated pancreatic cancer<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-overview\" class=\"wp-block-heading\">Clinical Development Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase Ib\/III<\/td><\/tr><tr><td><strong>Geography<\/strong><\/td><td>China<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>First-line KRAS-mutated pancreatic cancer<\/td><\/tr><tr><td><strong>Combination Regimen<\/strong><\/td><td>JAB-23E73 + nab-paclitaxel + gemcitabine<\/td><\/tr><tr><td><strong>Dosing Milestone<\/strong><\/td><td>First patient dosed on 20 Jul 2026<\/td><\/tr><tr><td><strong>Next Milestone<\/strong><\/td><td>Phase Ib safety data expected Q1 2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-therapeutic-rationale\" class=\"wp-block-heading\">Drug Profile &amp; Therapeutic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> JAB-23E73 \u2013 orally administered pan-KRAS inhibitor<\/li>\n\n\n\n<li><strong>Target:<\/strong> Pan-KRAS inhibition (all common KRAS mutations)<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Addresses one of oncology&#8217;s most challenging targets with high unmet need<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Independently developed by Jacobio with global patent protection<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> KRAS mutations show extremely high incidence in pancreatic cancer (>90% of cases), historically considered &#8220;undruggable&#8221;<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-partnership-framework\" class=\"wp-block-heading\">Strategic Partnership Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Arrangement<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Rights (ex-China)<\/strong><\/td><td>Exclusive license granted to <strong>AstraZeneca<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NYSE: AZN<\/a>)<\/td><\/tr><tr><td><strong>Mainland China<\/strong><\/td><td>Joint development and commercialization by Jacobio and AstraZeneca<\/td><\/tr><tr><td><strong>Commercial Implications<\/strong><\/td><td>Leverages AstraZeneca&#8217;s global oncology expertise while maintaining Jacobio&#8217;s strong China presence<\/td><\/tr><tr><td><strong>Revenue Sharing<\/strong><\/td><td>Not disclosed; typical co-development structure for China market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-context-amp-opportunity\" class=\"wp-block-heading\">Market Context &amp; Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pancreatic Cancer Landscape:<\/strong> One of the most lethal malignancies with five-year survival rate below 10%<\/li>\n\n\n\n<li><strong>KRAS Prevalence:<\/strong> Mutations present in >90% of pancreatic ductal adenocarcinoma cases<\/li>\n\n\n\n<li><strong>Current Treatment Gap:<\/strong> Limited effective targeted therapies for KRAS-mutated pancreatic cancer<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> JAB-23E73 represents one of the few pan-KRAS inhibitors in late-stage clinical development globally<\/li>\n\n\n\n<li><strong>Market Potential:<\/strong> Global pancreatic cancer therapeutics market projected to reach $4.2 billion by 2030, with KRAS-targeted therapies commanding premium pricing<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, partnership arrangements, and market opportunities for JAB-23E73. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, competitive dynamics, and partnership execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072000020_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026072000020_c.\"><\/object><a id=\"wp-block-file--media-9ca2da39-3f95-452e-8850-de2ead8263aa\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072000020_c.pdf\">2026072000020_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072000020_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9ca2da39-3f95-452e-8850-de2ead8263aa\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) announced that the first patient has been dosed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[130,16,62,895,154,4621],"class_list":["post-70253","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-astrazeneca","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-1167","tag-jacobio-pharmaceuticals","tag-nyse-azn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jacobio Launches Phase Ib\/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) announced that the first patient has been dosed in a Phase Ib\/III clinical trial in China evaluating JAB-23E73, an orally administered pan-KRAS inhibitor, in combination with nab-paclitaxel and gemcitabine for the first-line treatment of KRAS-mutated pancreatic cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70253\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jacobio Launches Phase Ib\/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca\" \/>\n<meta property=\"og:description\" content=\"Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) announced that the first patient has been dosed in a Phase Ib\/III clinical trial in China evaluating JAB-23E73, an orally administered pan-KRAS inhibitor, in combination with nab-paclitaxel and gemcitabine for the first-line treatment of KRAS-mutated pancreatic cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70253\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T03:17:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-20T03:17:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70253#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70253\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jacobio Launches Phase Ib\\\/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca\",\"datePublished\":\"2026-07-20T03:17:22+00:00\",\"dateModified\":\"2026-07-20T03:17:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70253\"},\"wordCount\":335,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 1167\",\"Jacobio Pharmaceuticals\",\"NYSE:\u202fAZN\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70253#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70253\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70253\",\"name\":\"Jacobio Launches Phase Ib\\\/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-20T03:17:22+00:00\",\"dateModified\":\"2026-07-20T03:17:24+00:00\",\"description\":\"Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) announced that the first patient has been dosed in a Phase Ib\\\/III clinical trial in China evaluating JAB-23E73, an orally administered pan-KRAS inhibitor, in combination with nab-paclitaxel and gemcitabine for the first-line treatment of KRAS-mutated pancreatic cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70253#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70253\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70253#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jacobio Launches Phase Ib\\\/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jacobio Launches Phase Ib\/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca - Insight, China&#039;s Pharmaceutical Industry","description":"Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) announced that the first patient has been dosed in a Phase Ib\/III clinical trial in China evaluating JAB-23E73, an orally administered pan-KRAS inhibitor, in combination with nab-paclitaxel and gemcitabine for the first-line treatment of KRAS-mutated pancreatic cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70253","og_locale":"en_US","og_type":"article","og_title":"Jacobio Launches Phase Ib\/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca","og_description":"Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) announced that the first patient has been dosed in a Phase Ib\/III clinical trial in China evaluating JAB-23E73, an orally administered pan-KRAS inhibitor, in combination with nab-paclitaxel and gemcitabine for the first-line treatment of KRAS-mutated pancreatic cancer.","og_url":"https:\/\/flcube.com\/?p=70253","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-20T03:17:22+00:00","article_modified_time":"2026-07-20T03:17:24+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70253#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70253"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jacobio Launches Phase Ib\/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca","datePublished":"2026-07-20T03:17:22+00:00","dateModified":"2026-07-20T03:17:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70253"},"wordCount":335,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","Cancer","Clinical trial approval \/ initiation","HKG: 1167","Jacobio Pharmaceuticals","NYSE:\u202fAZN"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70253#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70253","url":"https:\/\/flcube.com\/?p=70253","name":"Jacobio Launches Phase Ib\/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-20T03:17:22+00:00","dateModified":"2026-07-20T03:17:24+00:00","description":"Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) announced that the first patient has been dosed in a Phase Ib\/III clinical trial in China evaluating JAB-23E73, an orally administered pan-KRAS inhibitor, in combination with nab-paclitaxel and gemcitabine for the first-line treatment of KRAS-mutated pancreatic cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70253#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70253"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70253#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jacobio Launches Phase Ib\/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70253"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70253\/revisions"}],"predecessor-version":[{"id":70255,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70253\/revisions\/70255"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}